Agenda

• Welcome & Introductions

• Resolutions (Adam Reynolds, Non-executive Chairman)

• Business update with Lyn Rees (CEO)

• Q&A

• Close
Presenting Team

Adam Reynolds
Non-executive Chairman

Lyn Rees
CEO

Barry Hextall
CFO

Hayden Jeffreys
COO
Statement and Resolutions
Adam Reynolds: Non-executive Chairman

AGM statement RNS

Ordinary resolutions

1. To receive and adopt the Annual Report and Accounts for the year ended 31 March 2020
2. To re-elect Nicholas Mustoe
3. To re-elect Lyn Rees
4. To re-elect Hayden Jeffreys
5. To re-appoint Saffery Champness LLP as auditors
6. To authorise the Directors to determine Auditors’ remuneration
7. To authorise the Directors to allot shares or equity securities as described in the Notice of Meeting

Special resolution
8. To authorise the Directors to allot shares or equity securities for cash as described in the Notice of Meeting
Business update
Lyn Rees - CEO
Yourgene Health
Company Overview

• International molecular diagnostics group developing and commercialising genetic screening products and services

• Proprietary DNA analysis technology used to develop safer and improved non-invasive screening tests

• Strong track record of successful M&A:
  • Acquired Elucigene Diagnostics in April 2019
  • Acquired AGX-DPNI SAS in March 2020
  • Acquired EX5 Genomics in July 2020
  • Acquired Coastal Genomics, Canada in August 2020

• Group has a suite of leading CE-IVD NGS & PCR products focused on reproductive health, precision medicine, NIPT and infectious diseases

• AIM listed (YGEN) on London Stock Exchange

• Headquarters in Manchester, UK with facilities in Singapore, US, Canada and Taiwan
Key Milestones for Yourgene Health plc: 6 months of execution

- **March ’20**
  - Acquisition of AGX-DPNI, France

- **June ’20**
  - IONA Nx NIPT Workflow
  - CE mark

- **July ’20**
  - Acquisition of EX5 Genomics

- **August ’20**
  - Annual Results
    - £16.6m revenue
  - Launch Clarigene SARS CoV-2 CE-IVD Kit
  - Fundraise of £16m and Acquisition of Coastal Genomics

- **September ’20**
  - Launch IONA Nx NIPT Workflow
  - IB L agreement with US
COVID-19 Testing Update

• We have expanded our capacity and from October expect to be able to process 10,000 samples / month through our expanded set of sample acquisition partners. This will generate accretive revenue each month.

• We are actively increasing this capacity to support the Government “moonshot” scheme using proceeds from the recent fundraise.

• ClariGene® SARS CoV-2 CE-IVD product currently being evaluated by over ten institutions and now in routine manufacture.
IONA® Nx Update

• Following the launch and CE mark of the IONA® Nx NIPT Workflow we are happy to update that all our target accounts have signed up to transition to IONA® NX

• AGX-DPNI SAS is on track to hit its first milestone following the acquisition in March 2020, with two IONA® NX labs now live and the remaining target customers all scheduled for transition in the coming weeks

• Roll-out of Nx to new territories is progressing well with regulatory submissions on track and advanced new customer negotiations underway for EU, Japan, Australia
US Growth

- New non-exclusive marketing and distribution agreement signed for US with Immuno-Biological Laboratories Inc (IBL-America) who will be marketing some of the reproductive health and molecular genetics tests including:
  - DPYD (RUO)
  - QST*R XY (RUO)
  - QST*R Pregnancy Loss (RUO)
  - Male Factor Infertility (RUO)
  - Cystic Fibrosis (RUO)

  Addressable market of over £30 million

- New collaboration in reproductive health for Yourgene Flex™ Software with a prestigious partner which we expect to contribute revenue from H2 onwards, expect more visibility in October
Yourgene product & service portfolio is growing

Strategic growth focus:

• Product and service portfolio expansion:
  • DPYD launch - 20 accounts and growing
  • Yourgene Flex Analysis – launching in the US & Japan
  • IONA® Nx NIPT Workflow launch – line in Europe, global roll out underway
  • Clarigene SARS CoV-2 CE-IVD
  • COVID-19 test service launch
  • Consolidation of our Genomic Research Services – coming soon
Expanding our Genomic Research Services

• Yourgene is a full lifecycle service partner in the molecular diagnostics industry with:
  • Biomarker discovery
  • Clinical sample processing
  • Test development
  • Regulatory approval
  • Manufacturing and commercialisation

• Enhances our full offering for our partnership contract product development programmes

• Opens up new market with Clinical Research Organisations bringing us closer to Pharma/Biotech

• Investment in new re-fitted labs in Citylabs, Manchester and plans to mirror this in Taiwan in 2021 to support APAC contract opportunities
M&A Update
Coastal Genomics

• Integration Team established and key milestones mapped out with strong focus on commercial and revenue realisation as key priority
  • Virtual meetings scheduled with Coastal key customer and prospective partners
  • Commercial team training for range selling scheduled
  • IT and accounting integration in progress
  • Resource mapping underway
  • New commercial opportunities identified
Outlook

- Core business has been resilient during pandemic first phase and momentum building with fundamental growth drivers intact
- We have a strong pipeline in place to deliver a strong H2 in line with consensus analyst forecasts for the core business
- In addition, we expect to deliver accretive COVID-19 revenues this year
- Next financial calendar events:
  - Mid-Oct: half year trading update
  - Dec: half year results
Questions & Answers
• Thank you for joining us for the first virtual Yourgene Health plc AGM
• Thanks to all our presenters and to “Investor Meet Company” for hosting the event on their platform
• Any questions that we didn’t have time to answer we will try to answer via the IMC portal
• A copy of this presentation and the recording will also be made available on the IMC portal and the Yourgene Health website

https://www.investormeetcompany.com/yourgene-health-plc/

To be kept up to date with Yourgene Health plc news and to receive relevant investor communications on the Company going forward, please email Walbrook PR at yourgene@walbrookpr.com to subscribe